Literature DB >> 12772512

Technology evaluation: lerdelimumab, Cambridge Antibody Technology.

M Francesca Cordeiro1.   

Abstract

Cambridge Antibody Technology is developing lerdelimumab (CAT-152), the lead in a series of human anti-TGF beta 2 antibodies, for its potential in preventing post-operative scarring in patients undergoing surgery for glaucoma (trabulectomy). It also has potential for the treatment of fibrosis, cataract, retinopathy and connective tissue disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12772512

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

Review 1.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 2.  Targeting the transforming growth factor-beta signaling pathway in human cancer.

Authors:  Nagathihalli S Nagaraj; Pran K Datta
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

3.  A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis).

Authors:  Mark Brian Sherwood
Journal:  Trans Am Ophthalmol Soc       Date:  2006

4.  The role of focal adhesion kinase in the TGF-β-induced myofibroblast transdifferentiation of human Tenon's fibroblasts.

Authors:  Samin Hong; Jong Bok Lee; Yoko Iizuka; Yoo Kyung Song; Gong Je Seong; Sueng-Han Han
Journal:  Korean J Ophthalmol       Date:  2012-01-14

Review 5.  Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.

Authors:  Kazuya Nagano; Yasuo Tsutsumi
Journal:  Viruses       Date:  2021-01-25       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.